COVID-19 Updates from Celltex Therapeutics Learn More

Rick Perry Discusses Celltex's COVID-19 Clinical Trials on Fox News TV Watch Now

Clinical Research

Ongoing Clinical Trials

We have dedicated years to researching the safety and efficacy of MSCs for therapeutic use and have produced MSCs for over 9,000 therapies without incurring any adverse events.

Our ability to produce proprietary MSCs, our unique network of certified administering physicians and our positive, collaborative relationships with the U.S. FDA and COFEPRIS (Mexico’s equivalent to the FDA) make us a leader in the stem cell sector.

View the Clinical Trials

Leading the Way in Stem Cell Banking & Therapy

About Celltex Therapeutics

We are the nation’s leading commercial autologous (your own) adipose (fat)-derived MSC cryopreservation company and focus on spearheading breakthroughs in regenerative medicine using MSCs.

We also produce specialized allogeneic (donor) MSCs for use in clinical trials. Currently, Celltex has six ongoing clinical trials in two countries and one major partnership study with Texas A&M University.

The Celltex Difference

How It Works

We use our own proprietary technology to isolate, cryopreserve and culture hundreds of millions of identical and genetically stable MSCs in our state-of-the-art, FDA current Good Manufacturing Practices (cGMP)-compliant laboratory.

Celltex-produced MSCs are used in a range of therapies including immune system support, severe COVID-19 symptoms, injuries and chronic pain, as well as for many other conditions, including vascular, autoimmune and degenerative diseases, such as multiple sclerosis, severe arthritis, Parkinson’s disease and Alzheimer’s disease.

Clinical Trials in the U.S.

In the U.S., the following clinical trials are in progress:

COVID-19

Phase II

Phase II clinical trial using autologous MSCs as prophylactic (preventative) medicine for individuals at high risk of contracting COVID-19.

Learn More

Severe COVID-19 Symptoms

Phase II

Phase II clinical trial using allogeneic MSCs as a treatment for individuals with severe COVID-19 symptoms has been submitted to the FDA for approval to proceed.

Rheumatoid Arthritis

Phase I/IIa

Phase I/IIa clinical trial using autologous MSCs for Rheumatoid arthritis.

Learn More

Osteoarthritis

Phase II

Phase II clinical trial using autologous MSCs for osteoarthritis.

Learn More

Alzheimer’s Disease

Texas A&M University Partnership

Major partnership study with Texas A&M University IRM using proprietary A-1™ Exosomes for treatment of Alzheimer’s disease.

Clinical Trials in Mexico

In Mexico, the following clinical trials are in progress:

Rheumatoid Arthritis, Osteoarthritis & Secondary Conditions

Phase IIb

Phase IIb clinical trial using autologous MSCs for rheumatoid arthritis and osteoarthritis, as well as secondary conditions and diseases that cause a deterioration of quality of life, is more than half-way completed with excellent results so far.

This trial is being conducted at Hospital Galenia, a private hospital in Cancun.

Severe COVID-19 Symptom

Phase III

Phase III clinical trial using allogeneic MSCs as adjuvent treatment for severe COVID-19 symptoms has been submitted to COFEPRIS.

Clinical Research

Committed to Leading the Future of Regenerative Medicine

Our industry leadership and visionary approach continue to drive us to improve the quality of life of thousands of individuals, with a concerted focus to make this therapy accessible to all in the near future.

Email Icon

News & Information

Stay in the know about Celltex

Sign up to receive news, announcements, updates and offers about the latest happenings at Celltex.

I consent to the transfer and validation of my email address in conjunction with this email service, and I understand that I may withdraw my consent and unsubscribe at any time.

Attend our upcoming Zoom Webinar

Join us Thursday, December 3, 2020, from 11:00 am – 12:00 pm CST for one of our FREE educational Zoom webinars to discover how your own stem cells can lead to proven results and an improved quality of life.

Learn More

There is no cost to attend the webinar, but attendance is limited. RSVP today to reserve your spot.